Johnson & Johnson reports promising early results for targeted bladder cancer therapy
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
The trial will enroll up to 42 patients in Finland across four cohorts
This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Launches advanced bone density systems in India & Dubai
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
Subscribe To Our Newsletter & Stay Updated